NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report)'s share price hit a new 52-week high on Thursday . The stock traded as high as $18.98 and last traded at $18.13, with a volume of 545408 shares. The stock had previously closed at $17.99.
Wall Street Analysts Forecast Growth
NPCE has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $17.00 price target on shares of NeuroPace in a report on Wednesday, May 14th. Wells Fargo & Company increased their price target on NeuroPace from $13.00 to $17.00 and gave the company an "overweight" rating in a research note on Thursday, January 30th. Finally, JPMorgan Chase & Co. upped their target price on shares of NeuroPace from $14.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, NeuroPace presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.00.
Read Our Latest Research Report on NPCE
NeuroPace Price Performance
The stock has a market cap of $384.57 million, a price-to-earnings ratio of -11.74 and a beta of 2.04. The company has a 50 day simple moving average of $12.77 and a 200-day simple moving average of $12.07. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03.
NeuroPace (NASDAQ:NPCE - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.05. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The business had revenue of $22.52 million for the quarter, compared to analyst estimates of $21.85 million. Research analysts expect that NeuroPace, Inc. will post -1 EPS for the current year.
Insiders Place Their Bets
In related news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the firm's stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $15.85, for a total transaction of $2,664,955.60. Following the completion of the transaction, the insider now directly owns 3,238,199 shares of the company's stock, valued at $51,325,454.15. This trade represents a 4.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 22.20% of the company's stock.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. First Light Asset Management LLC bought a new position in shares of NeuroPace in the first quarter valued at approximately $19,468,000. Driehaus Capital Management LLC purchased a new position in NeuroPace in the 1st quarter worth approximately $9,874,000. Armistice Capital LLC increased its position in shares of NeuroPace by 94.7% during the 1st quarter. Armistice Capital LLC now owns 1,153,614 shares of the company's stock valued at $14,178,000 after purchasing an additional 561,000 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of NeuroPace by 124.0% during the 1st quarter. Deutsche Bank AG now owns 924,274 shares of the company's stock valued at $11,359,000 after purchasing an additional 511,662 shares during the last quarter. Finally, Lord Abbett & CO. LLC bought a new position in NeuroPace during the 1st quarter worth approximately $5,727,000. Institutional investors and hedge funds own 78.83% of the company's stock.
About NeuroPace
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Recommended Stories
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
